News & Media

Kane Biotech and Avmor Sign Licensing Agreement for KBI Disinfectant in Canada

Kane Biotech Inc. a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has signed a non-exclusive licensing agreement with Avmor Ltd for the manufacturing, distribution and sales of the Company's KBI Antibacterial Hard Surface Disinfectant (KBI) for the Canadian market. Avmor is Canada's leading manufacturer of professional cleaning solutions for the janitorial, sanitation and foodservice markets. Details of the agreement are not disclosed.

The agreement provides Avmor, with the rights to manufacture, distribute and sell KBI with an associated period of market exclusivity for the Canadian marketplace. The Companies will work closely together on technical, marketing and additional development initiatives to advance new formulations and applications.

KBI has received the Therapeutic Products Directorate of Health Canada approval with the issuance of a Drug Identification Number or DIN (02374463) for the Canadian household domestic use market. The Company has also submitted its supplemental DIN application to Health Canada for label expansion to include the additional sites of use such as hospital, food processing, medical instruments, barn and institutional and industrial facilities.

The Canadian hard surface disinfectant market is estimated at $130 million per year and is driven by the recent outbreaks of infectious diseases caused by bacterial and viral pathogens. KBI is effective against antibiotic-resistant bacterial pathogens such as Methicillin-resistant S. aureus (MRSA, "superbug"), Pseudomonas aeruginosa, Vancomycin-Resistant Enterococci (VRE), Klebsiella pneumoniae and Acinetobacter baumannii. It is also very effective against dangerous E. coli O157, Listeria and Salmonella that caused recent outbreaks of food-borne diseases due to contamination in food processing facilities. Unlike the other commercial disinfectants, KBI has both antimicrobial and antibiofilm activity that not only kills the free-living bacteria but also eradicates biofilm-embedded bacteria, which can be up to 1000 times resistant to antimicrobials.

"This agreement with Kane Biotech allows Avmor to deliver our customers with the most innovative new technology on the market," stated Paul Goldin, Chief Sustainability Officer and Director of Marketing and Technical Services of Avmor. "Kane's expertise and unique biofilm solutions allow us to provide a product with a simple two pronged attack that first breaks down the biofilm then kill the bacteria once hiding in the biofilm."

"We are very pleased to be working with Avmor to commercialize KBI. Avmor is a leading manufacturer, has a well established market position and strength across the Canadian marketplace," stated Gord Froehlich, President and CEO of Kane Biotech. "Working with Avmor opens the door to a very exciting market for our disinfectant product bringing viable solutions to the sanitation industry."

Click here to read the full story.

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe